Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Encorafenib and Binimetinib in BRAF V600 Mutant Melanoma
NCT01909453Phase 3Completed
- Sponsor
- Pfizer
- Start
- Sep 2013
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 29
01
Overview
A Phase 3 trial of encorafenib, binimetinib in melanoma, sponsored by Pfizer. Started Sep 2013; status: completed.
02
Drugs
encorafenibbinimetinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01909453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01909453.